8-K: OSR Health Faces Nasdaq Delisting Hearing

OSR Health has scheduled a Nasdaq hearing for September 29, 2026, to appeal the delisting determination and seek continued listing of its securities.

Summary

• OSR Health received notification that the Nasdaq Hearings Panel has scheduled a hearing for September 29, 2026, at 10:00 a.m. Eastern Time.
• This hearing is to appeal the Staff's delisting determination and request the continued listing of the company's securities on Nasdaq.
• Trading in OSR Health's securities was suspended at the opening of business on August 26, 2026.
• The company is preparing a plan to regain and sustain compliance with Nasdaq's continued listing requirements.
• There is no guarantee that the Panel will grant the request for continued listing or that the company will regain compliance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the ongoing trading suspension and the uncertainty surrounding the Nasdaq listing, despite the company's efforts to appeal.

Positives

• The company has requested a hearing to appeal the delisting determination, indicating an effort to maintain its Nasdaq listing.
• The timely hearing request has stayed the filing of a Form 25-NSE, preventing immediate formal delisting pending the Panel's decision.

Negatives

• Trading of OSR Health's securities has been suspended since August 26, 2026.
• The company faces the risk of formal delisting from Nasdaq if its appeal is unsuccessful.
• There is no assurance that the company will be successful in its appeal or regain compliance with Nasdaq's listing requirements.

Risks

• The primary risk is the potential formal delisting of OSR Health's securities from The Nasdaq Stock Market LLC.
• There is uncertainty regarding the outcome of the Nasdaq Hearings Panel decision.
• Failure to regain and sustain compliance with Nasdaq's continued listing requirements poses a significant risk.
• The suspension of trading limits liquidity and investor access to the company's securities.

Future Outlook

The company is preparing a comprehensive plan to regain and sustain compliance with Nasdaq's continued listing requirements and intends to advocate vigorously for its continued listing. However, there can be no assurance that the Panel will grant the request or that the company will maintain its listing.

Management Comments

• The Company is preparing its presentation to the Panel and intends to present a comprehensive plan to regain and sustain compliance with the applicable Nasdaq continued listing requirements.
• The Company is preparing diligently for the hearing, at which we intend to advocate vigorously for the Companys continued listing of its securities on Nasdaq.
• There can be no assurance that the Panel will grant the Companys request for continued listing or that the Company will regain compliance with Nasdaqs listing requirements.

Industry Context

StockSavvy.ai notes that maintaining a listing on major exchanges like Nasdaq is crucial for liquidity, investor confidence, and access to capital. Companies facing delisting often undergo significant restructuring or strategic shifts to meet exchange requirements.

Stakeholder Impact

• Shareholders face uncertainty regarding the continued trading and potential delisting of their investment.
• The trading suspension limits the liquidity of shares for existing investors.
• Potential investors may be deterred by the delisting risk and trading suspension.

Next Steps

• Participate in the Nasdaq Hearings Panel hearing on September 29, 2026.
• Present a comprehensive plan to regain and sustain compliance with Nasdaq's continued listing requirements.
• Await the Panel's decision regarding the continued listing of OSR Health's securities on Nasdaq.

Key Dates

Recommendation

The company is actively working to resolve its listing issues, but the outcome remains uncertain. A hold recommendation reflects the significant risk of delisting balanced against the company's efforts to comply and the potential for a positive resolution.

Keywords

Nasdaq Listing, Delisting, Trading Suspension, Securities Appeal, Compliance Plan, Hearings Panel